Familial Cancer

, Volume 6, Issue 1, pp 113–119 | Cite as

Improved survival in BRCA2 carriers with ovarian cancer

  • Tuya Pal
  • Jenny Permuth-Wey
  • Rachna Kapoor
  • Alan Cantor
  • Rebecca Sutphen
Original Paper



The objective of this study was to investigate survival of ovarian cancer patients with BRCA1 and BRCA2 mutations compared to those without mutations in a population-based sample of incident epithelial ovarian cancer cases.


Follow-up for vital status was performed on a population-based sample of 232 women with incident epithelial ovarian cancer recruited between December 13, 2000 and September 30, 2003 in the Tampa Bay area. Survival analysis using Cox regression was performed on (1) all 232 cases and (2) the 209 invasive epithelial ovarian cancer cases. Results of the two analyses were similar, thus data involving the 209 invasive epithelial cancer cases are presented, as this was judged to be more clinically relevant.


In the multivariate analysis, BRCA status and stage were statistically significant, and were adjusted for in the survival analysis model. The Kaplan–Meier method estimated expected survival at 4 years of 83% of BRCA2 carriers compared to 37% of BRCA1 carriers and 12% of non-carriers. There was a statistically significant difference between BRCA2 carriers and non-carriers (p = 0.013). No statistically significant survival differences were seen for BRCA1 carriers when compared with either BRCA2 carriers or non-carriers.


These data suggest that BRCA2 mutation carriers with ovarian cancer may have better survival than BRCA1 carriers and non-carriers. The etiology of this possible survival advantage is currently unknown. Larger studies are needed to confirm these results and to clarify their etiology and clinical significance.


hereditary ovarian cancer carcinoma BRCA1 BRCA2 Survival 


  1. 1.
    Whittemore AS (1994) Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol 55:S15–S19PubMedCrossRefGoogle Scholar
  2. 2.
    Risch HA, McLaughlin JR, Cole DE et al (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700–710PubMedCrossRefGoogle Scholar
  3. 3.
    Pal T, Permuth-Wey J, Betts JA et al (2005) BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104:2807–2816PubMedCrossRefGoogle Scholar
  4. 4.
    Narod S, Ford D, Devilee P et al (1995) Genetic heterogeneity of breast–ovarian cancer revisited. Breast Cancer Linkage Consortium. Am J Hum Genet 57:957–958PubMedGoogle Scholar
  5. 5.
    Frank TS, Manley SA, Olopade OI et al (1998) Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16:2417–2425PubMedGoogle Scholar
  6. 6.
    Ford D, Easton DF, Bishop D (1994) Tea: risks of cancer in BRCA1 mutation carriers. Lancet 343:692–695PubMedCrossRefGoogle Scholar
  7. 7.
    Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408PubMedCrossRefGoogle Scholar
  8. 8.
    Berchuck A, Heron KA, Carney ME et al (1998) Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 4:2433–2437PubMedGoogle Scholar
  9. 9.
    Bjorge T, Lie AK, Hovig E et al (2004) BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study. Br J Cancer 91:1829–1834PubMedCrossRefGoogle Scholar
  10. 10.
    Khoo US, Ngan HY, Cheung AN et al (2000) Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations. Hum Mutat 16:88–89PubMedCrossRefGoogle Scholar
  11. 11.
    Malander S, Ridderheim M, Masback A et al (2004) One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer 40:422–428PubMedCrossRefGoogle Scholar
  12. 12.
    Matsushima M, Kobayashi K, Emi M et al (1995) Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Hum Mol Genet 4:1953–1956PubMedCrossRefGoogle Scholar
  13. 13.
    Menkiszak J, Gronwald J, Gorski B et al (2003) Hereditary ovarian cancer in Poland. Int J Cancer 106:942–945PubMedCrossRefGoogle Scholar
  14. 14.
    Modan B, Hartge P, Hirsh-Yechezkel G et al (2001) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345:235–240PubMedCrossRefGoogle Scholar
  15. 15.
    Rafnar T, Benediktsdottir KR, Eldon BJ et al (2004) BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. Eur J Cancer 40:2788–2793PubMedCrossRefGoogle Scholar
  16. 16.
    Rubin SC, Blackwood MA, Bandera C et al (1998) BRCA1, BRCA2 and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 178:670–677PubMedCrossRefGoogle Scholar
  17. 17.
    Sekine M, Nagata H, Tsuji S et al (2001) Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population. Clin Cancer Res 7:3144–3150PubMedGoogle Scholar
  18. 18.
    Stratton JF, Gayther SA, Russell P et al (1997) Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 336:1125–1130PubMedCrossRefGoogle Scholar
  19. 19.
    Takahashi H, Behbakht K, McGovern PE et al (1995) Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 55:2998–3002PubMedGoogle Scholar
  20. 20.
    Van Der Looij M, Szabo C, Besznyak I et al (2000) Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer 86:737–740CrossRefGoogle Scholar
  21. 21.
    Anton-Culver H, Cohen PF, Gildea ME et al (2000) Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 36:1200–1208PubMedCrossRefGoogle Scholar
  22. 22.
    Majdak EJ, De Bock GH, Brozek I et al (2005) Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases—preliminary report. Eur J Cancer 41:143–150PubMedCrossRefGoogle Scholar
  23. 23.
    American Cancer Society Inc (2005) Cancer facts & figures 2005. American Cancer Society Inc, AtlantaGoogle Scholar
  24. 24.
    Mok SC, Chao J, Skates S et al (2001) Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 93:1458–1464PubMedCrossRefGoogle Scholar
  25. 25.
    Schink JC (1999) Managing the care of patients with advanced ovarian cancer. Semin Oncol 26:59–61PubMedGoogle Scholar
  26. 26.
    Schwartz PE, Taylor KJ (1995) Is early detection of ovarian cancer possible? Ann Med 27:519–528PubMedGoogle Scholar
  27. 27.
    Taylor KJ, Schwartz PE (1994) Screening for early ovarian cancer. Radiology 192:1–10PubMedGoogle Scholar
  28. 28.
    Greenlee RT, Hill-Harmon MB, Murray T et al (2001) Cancer statistics, 2001. CA Cancer J Clin 51:15–36PubMedCrossRefGoogle Scholar
  29. 29.
    Cass I, Baldwin RL, Varkey T et al (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187–2195PubMedCrossRefGoogle Scholar
  30. 30.
    Cortez D, Wang Y, Qin J et al (1999) Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286:1162–1166PubMedCrossRefGoogle Scholar
  31. 31.
    Husain A, He G, Venkatraman ES et al (1998) BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58:1120–1123PubMedGoogle Scholar
  32. 32.
    Yang H, Jeffrey PD, Miller J et al (2002) BRCA2 function in DNA binding and recombination from a BRCA2–DSS1–ssDNA structure. Science 297:1837–1848PubMedCrossRefGoogle Scholar
  33. 33.
    Aida H, Takakuwa K, Nagata H et al (1998) Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 4:235–240PubMedGoogle Scholar
  34. 34.
    Ben David Y, Chetrit A, Hirsh-Yechezkel G et al (2002) Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20:463–466PubMedCrossRefGoogle Scholar
  35. 35.
    Boyd J, Sonoda Y, Federici MG et al (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260–2265PubMedCrossRefGoogle Scholar
  36. 36.
    Buller RE, Anderson B, Connor JP et al (1993) Familial ovarian cancer. Gynecol Oncol 51:160–166PubMedCrossRefGoogle Scholar
  37. 37.
    Rubin SC, Benjamin I, Behbakht K et al (1996) Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335:1413–1416PubMedCrossRefGoogle Scholar
  38. 38.
    Johannsson OT, Ranstam J, Borg A et al (1998) Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 16:397–404PubMedGoogle Scholar
  39. 39.
    Pharoah PD, Easton DF, Stockton DL et al (1999) Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res 59:868–871PubMedGoogle Scholar
  40. 40.
    Ozols RF, Rubin SC, Thomas G et al (1997) Epithelial ovarian cancer. In Hoskins WJ, Perez CA, Young RC (eds) Principles and principles of gynecologic oncology. Lippincott-Raven Publishers, Philadelphia, p 958Google Scholar
  41. 41.
    World Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO, Geneva, SwitzerlandGoogle Scholar
  42. 42.
    Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20:1480–1490PubMedCrossRefGoogle Scholar
  43. 43.
    Petrij-Bosch A, Peelen T, van Vliet M et al (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17:341–345PubMedCrossRefGoogle Scholar
  44. 44.
    The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. Am J Hum Genet 67:207–212, 2000Google Scholar
  45. 45.
    Unger MA, Nathanson KL, Calzone K et al (2000) Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 67:841–850PubMedCrossRefGoogle Scholar
  46. 46.
    Rohlfs EM, Puget N, Graham ML et al (2000) An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosomes Cancer 28:300–307PubMedCrossRefGoogle Scholar
  47. 47.
    Ward BC, Hendrikson CA, Gaglio T et al (2002) Identification of a novel 26 kb deletion in BRCA1 haplotype pair analysis [abstract]. Am J Hum Genet 71:249Google Scholar
  48. 48.
    Rubin SC, Benjamin SC, Behbakht K et al (1997) Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA-1. N Engl J Med 335:1413–1416CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2006

Authors and Affiliations

  • Tuya Pal
    • 1
    • 3
    • 4
  • Jenny Permuth-Wey
    • 1
    • 3
  • Rachna Kapoor
    • 2
  • Alan Cantor
    • 2
    • 3
  • Rebecca Sutphen
    • 1
    • 3
    • 4
  1. 1.Division of Cancer Prevention and ControlH. Lee Moffitt Cancer Center and Research InstituteTampaUSA
  2. 2.Biostatistics CoreH. Lee Moffitt Cancer Center and Research InstituteTampaUSA
  3. 3.Department of Interdisciplinary Oncology, College of MedicineThe University of South FloridaTampaUSA
  4. 4.Department of Pediatrics, College of Medicine, All Children’s HospitalThe University of South FloridaSt PetersburgUSA

Personalised recommendations